Related references
Note: Only part of the references are listed.A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas
Stephane Goutagny et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development
Jeremie Vitte et al.
NATURE COMMUNICATIONS (2017)
mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors
Clare F. Malone et al.
CANCER DISCOVERY (2017)
Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1
Scott Troutman et al.
ONCOTARGET (2016)
Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas
Stephane Goutagny et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas
Roberta L. Beauchamp et al.
ONCOTARGET (2015)
White matter compromise predicts poor intellectual outcome in survivors of pediatric low-grade glioma
Fang Liu et al.
NEURO-ONCOLOGY (2015)
Neurofibromin Deficiency-Associated Transcriptional Dysregulation Suggests a Novel Therapy for Tibial Pseudoarthrosis in NF1
Nandina Paria et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors
William Lee et al.
NATURE GENETICS (2014)
Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1
Jean de la Croix Ndong et al.
NATURE MEDICINE (2014)
Optimizing biologically targeted clinical trials for neurofibromatosis
David H. Gutmann et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis
Eric P. Rahrmann et al.
NATURE GENETICS (2013)
Recommendations for imaging tumor response in neurofibromatosis clinical trials
Eva Dombi et al.
NEUROLOGY (2013)
18-Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) Evaluation of Nodular Lesions in Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas (PN) or Malignant Peripheral Nerve Sheath Tumors (MPNST)
Holly Meany et al.
PEDIATRIC BLOOD & CANCER (2013)
Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types
Marianne F. James et al.
MOLECULAR CANCER RESEARCH (2012)
Peripheral muscle weakness in RASopathies
David A. Stevenson et al.
MUSCLE & NERVE (2012)
Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas
Matthias A. Karajannis et al.
NEURO-ONCOLOGY (2012)
Atypical Neurofibromas in Neurofibromatosis Type 1 are Premalignant Tumors
Eline Beert et al.
GENES CHROMOSOMES & CANCER (2011)
NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth
Marianne F. James et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Parental distress, family functioning, and social support in families with and without a child with neurofibromatosis 1
Jennifer Reiter-Purtill et al.
JOURNAL OF PEDIATRIC PSYCHOLOGY (2008)
Evidence-based assessment, intervention and psychosocial care in pediatric oncology: A blueprint for comprehensive services across treatment
Anne E. Kazak et al.
JOURNAL OF PEDIATRIC PSYCHOLOGY (2007)
Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging
J Solomon et al.
COMPUTERIZED MEDICAL IMAGING AND GRAPHICS (2004)
Share Paper
